

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM381518

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Pozen Inc.		02/05/2016	Corporation: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	Deerfield Private Design Fund III, L.P.
<b>Street Address:</b>	780 Third Avenue, 37th Floor
<b>City:</b>	New York
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10017
<b>Entity Type:</b>	Limited Partnership: DELAWARE
<b>Name:</b>	Deerfield International Master Fund, L.P.
<b>Street Address:</b>	780 Third Avenue, 37th Floor
<b>City:</b>	New York
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10017
<b>Entity Type:</b>	Limited Partnership: VIRGIN ISLANDS, BRITISH
<b>Name:</b>	Deerfield Partners, L.P.
<b>Street Address:</b>	780 Third Avenue, 37th Floor
<b>City:</b>	New York
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10017
<b>Entity Type:</b>	Limited Partnership: DELAWARE

## PROPERTY NUMBERS Total: 12

Property Type	Number	Word Mark
<b>Serial Number:</b>	86011803	YOSPRALA
<b>Serial Number:</b>	86011838	QOTUDRO
<b>Serial Number:</b>	85851645	DUTAVI
<b>Serial Number:</b>	85844970	PABAZO
<b>Serial Number:</b>	85845036	OSPRANZA
<b>Registration Number:</b>	3945953	POZEN
<b>Registration Number:</b>	3959405	POZEN TRANSFORMING MEDICINE. TRANSFORMIN

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	3963238	TRANSFORMING MEDICINE. TRANSFORMING LIVE
Registration Number:	4462907	POZEN TRANSFORMING MEDICINE. TRANSFORMIN
Registration Number:	4451596	TRANSFORMING MEDICINE. TRANSFORMING LIVE
Registration Number:	4372803	POZEN
Registration Number:	4392547	POZEN

**CORRESPONDENCE DATA**

Fax Number: 3129021061

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 312.577.8034

Email: oscar.ruiz@kattenlaw.com

Correspondent Name: Oscar Ruiz c/o Katten Muchin Rosenman

Address Line 1: 525 West Monroe Street

Address Line 4: Chicago, ILLINOIS 60661

**ATTORNEY DOCKET NUMBER:** 333285-117

**NAME OF SUBMITTER:** Oscar Ruiz

**SIGNATURE:** /Oscar Ruiz/

**DATE SIGNED:** 04/21/2016

**Total Attachments: 14**

source=IP Security Agreement#page1.tif  
source=IP Security Agreement#page2.tif  
source=IP Security Agreement#page3.tif  
source=IP Security Agreement#page4.tif  
source=IP Security Agreement#page5.tif  
source=IP Security Agreement#page6.tif  
source=IP Security Agreement#page7.tif  
source=IP Security Agreement#page8.tif  
source=IP Security Agreement#page9.tif  
source=IP Security Agreement#page10.tif  
source=IP Security Agreement#page11.tif  
source=IP Security Agreement#page12.tif  
source=IP Security Agreement#page13.tif  
source=IP Security Agreement#page14.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Agreement"), dated as of February 5, 2016, is by and between POZEN INC., a Delaware corporation ("Grantor") and Deerfield Private Design Fund III, L.P., Deerfield International Master Fund, L.P. and Deerfield Partners, L.P. (collectively the "Secured Party").

### WITNESSETH:

WHEREAS, pursuant to that certain Second Amended and Restated Facility Agreement, dated as of December 7, 2015 (the "Facility Agreement"), by and among Aralez Pharmaceuticals Inc. ("Borrower"), Tribute Pharmaceuticals Canada Inc. and Grantor, Secured Party has made loans to Borrower in accordance with the terms and conditions set forth therein; and

WHEREAS, to secure the Obligations under the Facility Agreement and Grantor's guaranty of the Obligations, Grantor has agreed to enter into this Agreement.

NOW, THEREFORE, in consideration of the mutual conditions and agreements set forth in this Agreement, and for good and valuable consideration, the receipt of which is hereby acknowledged, the Grantor and Secured Party, hereby agree as follows:

### SECTION 1. Definitions.

1.1 Generally. All references herein to the UCC shall mean the Uniform Commercial Code as in effect from time to time in the State of New York; provided, however, that if a term is defined in Article 9 of the UCC differently than in another Article thereof, the term shall have the meaning set forth in Article 9; provided further that, if by reason of mandatory provisions of law, perfection, or the effect of perfection or non-perfection, of the security interest in any IP Collateral or the availability of any remedy hereunder is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, "UCC" means the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions hereof relating to such perfection or effect of perfection or non-perfection or availability of such remedy, as the case may be.

1.2 Definition of Certain Terms Used Herein. Unless the context otherwise requires, all capitalized terms used but not defined herein shall have the meanings set forth in the Facility Agreement. In addition, as used herein, the following terms shall have the following meanings:

"Copyrights" shall mean all copyrights and like protections in each work of authorship or derivative work thereof of Grantor anywhere in the world, whether registered or unregistered and whether published or unpublished, including, without limitation, the copyright registrations and copyright applications listed on **EXHIBIT A** annexed hereto and made a part hereof, together with any goodwill of the business connected with, and symbolized by, any of the foregoing.

"Copyright Licenses" shall mean all agreements, whether written or oral, providing for the grant by or to Grantor of any right under any Copyright, including, without limitation, the agreements listed on **EXHIBIT A** annexed hereto and made a part hereof.

"Copyright Office" shall mean the United States Copyright Office or any other federal governmental agency which may hereafter perform its functions.

"Intellectual Property" shall have the meaning assigned to such term in Section 3 of this Agreement.

"IP Collateral" shall have the meaning assigned to such term in Section 2 of this Agreement.

"Licenses" shall mean, collectively, the Copyright Licenses, Patent Licenses, Trademark Licenses, and any other license providing for the grant by or to Grantor of any right under any Intellectual Property.

"Patents" shall mean all patents and applications for patents of Grantor and the inventions and improvements therein disclosed, and any and all divisions, revisions, reissues and continuations, continuations-in-part, extensions, and reexaminations of said patents anywhere in the world including, without limitation, the patent registrations and patent applications listed on **EXHIBIT B** annexed hereto and made a part hereof.

"Patent Licenses" shall mean all agreements, whether written or oral, providing for the grant by or to Grantor of any right under any Patent including, without limitation, the agreements listed on **EXHIBIT B** annexed hereto and made a part hereof.

"Permitted Liens" means Liens in favor of Secured Party.

"PTO" shall mean the United States Patent and Trademark Office or any other federal governmental agency which may hereafter perform its functions.

"Secured Obligations" shall mean the collective reference to (i) all Obligations of Grantor to Secured Party under the Facility Agreement, (ii) all obligations of Grantor under its guaranty of the Obligations and (iii) all obligations of Grantor under this Agreement, respectively (including, without limitation, default interest accruing at the then applicable rate provided in the Facility Agreement and interest accruing at the then applicable rate after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or like proceeding, relating to Grantor, and post-filing or post-petition interest, whether direct or indirect, absolute or contingent, due or to become due, or now existing or hereafter incurred, which may arise under, out of, or in connection with, the Facility Agreement, or any other document executed and delivered in connection therewith, in each case whether on account of principal, interest, fees, indemnities, costs, expenses or otherwise (including, without limitation, all reasonable fees and disbursements of counsel to Secured Party that are required to be paid by Grantor pursuant to the terms of any of the foregoing agreements).

"Trademarks" shall mean all trademarks, trade names, corporate names, company names, domain names, business names, fictitious business names, trade dress, trade styles, service marks, designs, logos and other source or business identifiers of Grantor anywhere in the world, whether registered or unregistered, including, without limitation, the trademark registrations and trademark applications listed on **EXHIBIT C** annexed hereto and made a part hereof, together with any goodwill of the business connected with, and symbolized by, any of the foregoing.

"Trademark Licenses" shall mean all agreements, whether written or oral, providing for the grant by or to Grantor of any right under any Trademark, including, without limitation, the agreements listed on **EXHIBIT C** annexed hereto and made a part hereof.

SECTION 2. Grant of Security Interest. As further security for the payment or performance, as the case may be, in full of the Secured Obligations, the Grantor hereby grants to Secured Party a lien and continuing security interest, with a power of sale (which power of sale shall be exercisable only following the occurrence and during the continuance of an Event of Default), in all of the present and future right, title and interest of Grantor in and to the following property, and each item thereof, whether now owned or existing or hereafter acquired or arising, together with all products, proceeds, substitutions, and accessions of or to any of the following property (collectively, the "IP Collateral"):

- (a) All Copyrights and Copyright Licenses;
- (b) All Patents and Patent Licenses;
- (c) All Trademarks and Trademark Licenses;
- (d) All other Licenses;
- (e) All renewals of any of the foregoing;
- (f) All of the following: all trade secrets, know-how and other proprietary information; works of authorship and other copyright works (including copyrights for computer programs), and all tangible and intangible property embodying the foregoing; inventions (whether or not patentable) and all improvements thereto; industrial design applications and registered industrial designs; books, records, writings, computer tapes or disks, flow diagrams, specification sheets, computer software, source codes, object codes, executable code, data, databases, and other physical manifestations, embodiments or incorporations of any of the foregoing, and any Licenses in any of the foregoing, and all other Intellectual Property and proprietary rights;
- (g) All General Intangibles connected with the use of, or related to, any and all of the foregoing (including, without limitation, all goodwill of Grantor and its business, products and services appurtenant to, associated with, or symbolized by, any Intellectual Property and the use thereof);

(h) All income, royalties, damages and payments now and hereafter due and/or payable under and with respect to any of the foregoing, including, without limitation, payments under all Licenses entered into in connection therewith and damages and payments for past or future infringements, misappropriations or dilutions thereof;

(i) The right to sue for past, present and future infringements, misappropriations, and dilutions of any of the foregoing; and

(j) All of the Grantor's rights corresponding to any of the foregoing throughout the world.

Notwithstanding anything herein, or in any other Loan Document, to the contrary, in no event shall the IP Collateral include any Excluded Property.

SECTION 3. Protection of Intellectual Property By Grantor. Except as set forth below in this Section 3, the Grantor shall undertake the following with respect to each of the items respectively described in Sections 2(a), (b), (c), (d), (e), (f) and (g) (collectively, the "Intellectual Property"):

(a) Pay all renewal fees and other fees and costs associated with maintaining the Intellectual Property and with the processing and prosecution of the Intellectual Property, if applicable, and take all other steps reasonably necessary to maintain each registration of the Intellectual Property, except, in each case, to the extent that the failure to do so could not reasonably be expected to have a Material Adverse Effect. For the sake of clarity, it shall not constitute a Material Adverse Effect for Grantor to allow any Intellectual Property to go abandoned, or otherwise dispose of such Intellectual Property to the extent permitted by the Facility Agreement, if, in Grantor's reasonable judgment and determination, such Intellectual Property is no longer material to the conduct of Grantor's business.

(b) At the Grantor's sole cost, expense, and risk, take any and all action which the Grantor reasonably deems necessary or desirable under the circumstances to pursue the processing and prosecution of each application for registration which is the subject of the security interest created herein and not abandon or delay any such efforts.

(c) At the Grantor's sole cost, expense, and risk, take any and all action reasonably necessary or desirable under the circumstances to protect the Intellectual Property from infringement, misappropriation or dilution, including, without limitation, the prosecution and defense of infringement actions.

SECTION 4. Grantor's Representations and Warranties. In addition to any representations and warranties contained in Guaranty, Grantor represents and warrants that:

(a) **EXHIBIT A** is a true, correct and complete list of all registered Copyrights owned by Grantor and all Copyright Licenses to which Grantor is a party as of the date hereof.

(b) **EXHIBIT B** is a true, correct and complete list of all registered Patents owned by Grantor and all Patent Licenses to which Grantor is a party as of the date hereof.

(c) **EXHIBIT C** is a true, correct and complete list of all registered Trademarks owned by Grantor and all Trademark Licenses to which Grantor is a party as of the date hereof.

(d) Except as set forth in **EXHIBITS A, B and C**, none of the Intellectual Property owned by Grantor is the subject of any licensing or franchise agreement pursuant to which Grantor is the licensor or franchisor as of the date hereof.

(e) All IP Collateral owned by Grantor is, and shall remain, free and clear of all Liens, encumbrances, or security interests in favor of any Person, other than Permitted Liens.

(f) To Grantor's knowledge, Grantor owns, or is licensed to use, all Intellectual Property necessary for the conduct of its business as currently conducted. No claim has been asserted and is pending by any Person challenging or questioning the use by Grantor of any of its Intellectual Property, or the validity or effectiveness of any of its Intellectual Property. To the Grantor's knowledge, the use by Grantor of the Intellectual Property does not infringe the rights of any Person in any material respect. No holding, decision or judgment has been rendered by any Governmental Authority which would limit, cancel or question the validity of, or Grantor's rights in, any Intellectual Property in any material respect.

(g) Grantor shall give Secured Party prompt written notice, with reasonable detail, following the occurrence of any of the following:

(i) Grantor's obtaining rights to, and filing applications for registration of, any new Intellectual Property, or otherwise acquiring ownership of any registered Intellectual Property.

(ii) Grantor's becoming entitled to the benefit of any material registered Intellectual Property whether as licensee or licensor.

(iii) Grantor's entering into any new Licenses with respect to any material Intellectual Property.

(iv) Grantor's knowing that any application or registration relating to any material Intellectual Property may, other than as provided in Section 3 above, become forfeited, abandoned or dedicated to the public, or of any adverse determination or development (including, without limitation, the institution of, or any such determination or development in, any proceeding in the PTO, the Copyright Office or any court or tribunal) regarding Grantor's ownership of, or

the validity or enforceability of, any material Intellectual Property or Grantor's right to register the same or to own and maintain the same.

SECTION 5. Agreement Applies to Future Intellectual Property.

(a) The provisions of this Agreement shall automatically apply to any such additional property or rights described in subsections (i), (ii), and (iii) of Section 4(g), above, all of which shall be deemed to be and treated as "Intellectual Property" within the meaning of this Agreement. Upon the acquisition by Grantor of any additional material Intellectual Property, Grantor shall promptly deliver to Secured Party an updated EXHIBIT A, B, and/or C (as applicable) to this Agreement and hereby authorizes the Lender to file, at Grantor's expense, such updated Exhibit as set forth in Section 5(b).

(b) Grantor shall execute and deliver, and have recorded, any and all agreements, instruments, documents and papers as the Lender may reasonably request to evidence Secured Party's security interest in any material Intellectual Property (including, without limitation, filings with the PTO, the Copyright Office or any similar office), and the Grantor hereby appoints Secured Party as its attorney-in-fact to execute and file all such writings for the foregoing purposes, all such acts of such attorney being hereby ratified and confirmed; provided, however, that Secured Party's taking of such action shall not be a condition to the creation or perfection of the security interest created hereby.

SECTION 6. Grantor's Rights To Enforce Intellectual Property. So long as no Event of Default has occurred and is continuing, the Grantor shall have the exclusive right to sue for past, present and future infringement of the Intellectual Property, including the right to seek injunctions and/or money damages in an effort by the Grantor to protect the Intellectual Property against encroachment by third parties, provided, however, that:

(a) The Grantor provides Secured Party with written notice of the Grantor's institution of any legal proceedings for enforcement of any IP Collateral;

(b) Any money damages awarded or received by the Grantor on account of such suit (or the threat of such suit) shall constitute IP Collateral; and

(c) Upon the occurrence and during the continuance of any Event of Default, the Lender, by notice to the Grantor, may terminate or limit the Grantor's rights under this Section 6.

SECTION 7. Grantor's Rights to License Intellectual Property. Grantor shall provide prompt written notice to Secured Party of the licensing of any Intellectual Property. Secured Party agrees that all rights of any licensee of the Intellectual Property shall survive any exercise of rights and remedies by Secured Party in connection with this Agreement, including any foreclosure and subsequent transfer of such Intellectual Property by Secured Party. Secured Party further agrees, following the reasonable request of the Grantor or any licensee of the Intellectual Property and at the Grantor's or such licensee's expense, to execute such documents



and to take such actions as may be reasonably requested by the Grantor or such licensee to preserve and protect the rights of any such licensee.

SECTION 8. Lender's Actions To Protect Intellectual Property. In the event of:

(a) Grantor's failure, within fifteen (15) days of written notice from Secured Party, to cure any failure by Grantor to observe or perform any of Grantor's covenants, agreements or other obligations hereunder; and/or

(b) the occurrence and continuance of any other Event of Default, Secured Party, acting in its own name or in that of Grantor, may (but shall not be required to) act in Grantor's place and stead and/or in Secured Party's own right in connection therewith.

SECTION 9. Rights Upon Default. Upon the occurrence and during the continuance of an Event of Default, in addition to all other rights and remedies, Secured Party may exercise all rights and remedies of a secured party under the Uniform Commercial Code as adopted in the State of New York, with respect to the Intellectual Property, in addition to which Secured Party may sell, license, assign, transfer, or otherwise dispose of the Intellectual Property, subject to those restrictions to which Grantor is subject under applicable law and by contract. Any Person may conclusively rely upon an affidavit of an officer of Secured Party that an Event of Default has occurred and that Secured Party is authorized to exercise such rights and remedies.

SECTION 10. Secured Party As Attorney-in-Fact.

(a) Grantor hereby irrevocably makes, constitutes and appoints Secured Party (and all officers, employees or agents designated by Secured Party) as and for Grantor's true and lawful agent and attorney-in-fact, and in such capacity Secured Party shall have the right, with power of substitution for Grantor and in Grantor's name or otherwise, for the use and benefit of Secured Party:

(i) To supplement and amend from time to time EXHIBITS A, B and C of this Agreement to include any newly developed, applied for, registered, or acquired Intellectual Property of Grantor and any intent-to-use Trademark applications for which a statement of use or an amendment to allege use has been filed and accepted by the PTO.

(ii) Following the occurrence and during the continuance of any Event of Default, to exercise any of the rights and powers referenced herein.

(iii) Following the occurrence and during the continuance of any Event of Default, to execute all such instruments, documents, and papers as the Secured Party reasonably determines to be necessary or desirable in connection with the exercise of such rights and remedies and to cause the sale, license, assignment, transfer, or other disposition of the Intellectual Property, subject to those restrictions to which Grantor is subject under applicable law and by contract.

(b) The power of attorney granted herein, being coupled with an interest, shall be irrevocable until this Agreement is terminated in writing by a duly authorized officer of Secured Party.

(c) Secured Party shall not be obligated to do any of the acts or to exercise any of the powers authorized by Section 10(a), but if Secured Party elects to do any such act or to exercise any of such powers, it shall not be accountable for more than it actually receives as a result of such exercise of power, and shall not be responsible to Grantor for any act or omission to act, except where a court of competent jurisdiction determines by final and nonappealable judgment that the subject act or omission to act has resulted from the gross negligence or willful misconduct of Secured Party.

SECTION 11. Lender's Rights. Any use by Secured Party of the Intellectual Property, as authorized hereunder in connection with the exercise of Secured Party's rights and remedies under this Agreement shall be without any liability for royalties or other related charges.

SECTION 12. Further Assurances. Grantor agrees, at its own expense, to execute, acknowledge, deliver and cause to be duly filed all such further documents, financing statements, agreements and instruments and take all such further actions as Secured Party may from time to time reasonably request to better assure, preserve, protect and perfect the security interest in the IP Collateral granted pursuant to this Agreement and the rights and remedies created hereby or the validity or priority of such security interest including the payment of any fees and taxes required in connection with the execution and delivery of this Agreement, the granting of the security interest and the filing of any financing statements or other documents in connection herewith or therewith.

SECTION 13. Choice of Laws. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to the conflicts of laws principles thereof other than Sections 5-1401 and 5-1402 of the General Obligations Law of such State.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement under seal as of the day and year first above written.

**GRANTOR:**

**POZEN INC.**

By: Adrian Adams  
Name: Adrian Adams  
Title: Chief Executive Officer

Address for Notices:  
1414 Raleigh Road, Suite 400  
Chapel Hill, North Carolina 27517

Fax: (610) 688-8251  
Email: aadams@pozen.com  
Attn: Chief Executive Officer

EXHIBIT A  
List of Copyrights and Copyright Licenses

**Copyright Registrations**

<u>Title</u>	<u>Serial No.</u>	<u>Registration No.</u>	<u>Registration Date</u>
--------------	-------------------	-------------------------	--------------------------

NONE

**Copyright Licenses**

NONE

**EXHIBIT B**

**List of Patents and Patent Licenses**

**Patent Registrations**

<b>Description</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Patent No.</b>	<b>Registration Date</b>
Method for delivering a pharmaceutical composition to patient in need thereof	12553107	9/3/09	9220698	12/29/15
Pharmaceutical compositions for the coordinated delivery of NSAIDs	14753195	6/29/15	9198888	12/1/15
Pharmaceutical compositions for the coordinated delivery of NSAIDs	14515627	10/16/14	9161920	10/20/15
Method for treating a patient at risk for developing an NSAID-associated ulcer	14593212	1/9/15	N/A	N/A
Controlled dosing of clopidogrel with gastric acid inhibition therapies	14344688	10/23/14	N/A	N/A
Method for treating a patient at risk for developing an NSAID-associated ulcer	12822612	6/24/10	8945621	2/3/15
Phased dosing of clopidogrel	14344699	10/9/14	N/A	N/A
Compositions and methods for delivery of omeprazole plus acetylsalicylic acid	14367972	6/23/14	N/A	N/A
Pharmaceutical compositions for the coordinated delivery of NSAIDs	14231971	4/1/14	8865190	10/21/14
Pharmaceutical compositions for the coordinated delivery of NSAIDs	14244471	4/3/14	8858996	10/14/14
Pharmaceutical compositions for the coordinated delivery of NSAIDs	14045156	10/3/13	8852636	10/7/14

Description	Application No.	Application Date	Patent No.	Registration Date
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs	13872832	4/29/13	N/A	N/A
Pharmaceutical compositions for the coordinated delivery of NSAIDs	13215855	8/23/11	8557285	10/15/13
Pharmaceutical compositions for the coordinated delivery of NSAIDs	13475446	5/18/12	N/A	N/A
Method for treating a patient in need of aspirin therapy	13345075	1/6/12	N/A	N/A
Pharmaceutical compositions for the coordinated delivery of NSAIDs	11129320	5/16/05	8206741	6/26/12
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs	13183983	7/15/11	N/A	N/A
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs	10414493	4/16/03	8022095	9/20/11
Method for treating a patient in need of aspirin therapy	12823082	6/24/10	N/A	N/A
Pharmaceutical compositions for the coordinated delivery of naproxen and esomeprazole	12553804	9/3/09	N/A	N/A
Dosage forms for administering combinations of drugs	11987970	12/6/7	N/A	N/A
Multilayer dosage forms containing NSAIDs	10741592	12/22/03	7332183	2/19/08
Dosage forms for administering combinations of drugs	11712969	3/2/07	N/A	N/A
Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID	11332795	1/7/06	N/A	N/A

116417601\_2

Description	Application No.	Application Date	Patent No.	Registration Date
Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an NSAID	11331036	1/13/06	N/A	N/A
Dosage form for treating gastrointestinal disorders	11328259	1/10/06	N/A	N/A
High potency dihydroergotamine compositions	10281982	10/29/02	7060694	6/13/06
Treatment of migraine headache	10255036	9/26/02	7030162	4/18/06
Pharmaceutical compositions for the coordinated delivery of NSAIDS	10158216	5/31/02	6926907	8/9/05
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs	09559753	4/27/00	6586458	7/1/03
High potency dihydroergotamine compositions	09526474	3/15/00	6495535	12/17/02
Treatment of migraine headache	09517751	3/3/00	6479551	11/12/02
Treatment of migraine headache	08966506	11/10/97	6077539	6/20/00
Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs	09151912	9/11/98	6060499	5/9/00
Formulation of 5-HT agonist and NSAID for treatment of migraine	08907826	8/14/97	5872145	2/16/99

#### Patent Licenses

116417601\_2

**EXHIBIT C**

**List of Trademarks and Trademark Licenses**

**Trademark Registrations**

Mark	Application No.	Application Date	Registration No.	Registration Date
YOSPRALA	86011803	7/16/13	N/A	N/A
QOTUDRO	86011838	7/16/13	N/A	N/A
DUTAVI	85851645	2/15/13	N/A	N/A
PABAZO	85844970	2/8/13	N/A	N/A
OSPRANZA	85845036	2/8/13	N/A	N/A
POZEN	77981045	11/13/09	3945953	4/12/11
POZEN	77981510	11/13/09	3959405	5/10/11
TRANSFORMING MEDICINE. TRANSFORMING LIVES				
TRANSFORMING MEDICINE. TRANSFORMING LIVES.	77981566	11/13/09	3963238	5/17/11
POZEN TRANSFORMING MEDICINE. TRANSFORMING LIVES.	77872304	11/13/09	4462907	1/7/14
TRANSFORMING MEDICINE. TRANSFORMING LIVES.	77872318	11/13/09	4451596	12/17/13
POZEN	77872440	11/13/09	4372803	7/23/13
POZEN	77872462	11/13/09	4392547	8/27/13

**Trademark Licenses**